Matrix metalloproteinase-2 (MMP-2) in T1-2N0 breast carcinoma

Breast Cancer Research and Treatment

Volumn 77, Issue 1, 2003, Pages 85-91

  Hirvonen, Riikka ^a   Talvensaari Mattila, Anne ^a   Pääkkö, Paavo ^a   Turpeenniemi Hujanen, Taina ^a,b  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

72 kDa type IV collagenase; Breast cancer; Gelatinase A; Prognostic factors

Indexed keywords

ESTROGEN RECEPTOR; GELATINASE A; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FINLAND; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0344951297     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021152910976     Document Type: Article

References (35)

1. Liotta LA, Wewer U, Rao NC, Schiffmann E, Stracke M, Guirguis R, Thorgeirsson U, Muschel R, Sobel M: Biochemical mechanisms of tumor invasion and metastases. Prog Clin Biol Res 256: 3-16, 1988
2. Liotta LA, Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Semin Cancer Biol 1: 99-106, 1990
3. Curran S, Murray GI: Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189: 300-308, 1999
4. D'Errico A, Garbisa S, Castronovo R, Stetler-Stevenson WG, Liotta LA, Grigioni WF: Augmentation of type IV collagenase and laminin receptors immunoreactivity associated with human breast, colon and gastric carcinoma progression. Mod Pathol 4: 239-246, 1991
5. Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, Stetler-Stevensson WG: Increased expression of the 72 kDa type IV collagenase in human colonic adenocarcinoma. Cancer Res 51: 439-444, 1991
6. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, Schiraldi O, Antonaci S: Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 97(4): 425-431, 2002
7. Sakata K, Shigemasa K, Nagai N, Ohama K: Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 17: 673-681, 2000
8. Ellenrieder V, Alber B, Lacher U, Hendler SF, Menke A, Boeck W, Wagner M, Wilda M, Friess H, Buchler M, Adler G, Gress TM: Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer 85: 14-20, 2000
9. Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG: Immunohistochemical distribution of type IV collagenase in normal, benign and malignant breast tissue. Am J Patrol 136: 585-589, 1990
10. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67: 1126-1131, 1993
11. Tryggvason K, Höyhtyä M, Pyke C: Type IV collagenases in invasive tumours. Breast Cancer Res Treat 24: 209-218, 1993
12. Visscher DW, Höyhtyä M, Ottosen SK, Liang C-M, Sarkar FH, Crissman D, Fridman R: Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59: 339-344, 1994
13. Jones JL, Glynn P, Walker RA: Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Patrol 189: 161-168, 1999
14. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y: Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 87: 602-611, 1996
15. Garbett EA, Reed MW, Brown NJ: Proteolysis in breast 1 and colorectal cancer. Br J Cancer 8: 287-293, 1999
16. Garbett EA, Reed MW, Stephenson TJ, Brown NJ: Proteolysis in human breast cancer. J Clin Patrol 53: 99-106, 2000
17. Höyhtyä M, Fridman R, Komarck D, Porter-Jordan K, Stetler-Stevenson WG, Liotta LA: Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissue with monoclonal antibodies. Int J Cancer 54: 500-505, 1994
18. Daidone M, Silvestrini R, D'Errico A, Di Fronzo G, Benini E, Mancini AM, Garbisa S, Liotta LA, Grigioni WF: Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer 48: 529-532, 1991
19. Tetu B, Brisson J, Lapointe H, Bernard P: Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancen Hum Patrol 29: 979-985, 1998
20. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Berner A, Bryne M, Reich R: High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 17: 799-808, 1999
21. Jäàlinoja J, Herva R, Korpela M, HöSyhtyä M, TurpeenniemiHujanen T: Matrix metalloproteinase-2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J Neuro-Oncol 46: 81-90, 2000
22. Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T: MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Breast Cancer Res Treat 58: 287-293, 1999
23. Talvensaari-Mattila A, Pääkkö P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen therapy. Breast Cancer Res Treat 65: 55-56, 2001
24. Scarff RW, Torloni H: Histological Typing of Breast Tumours. WHO, Geneva, 1986
25. Hsu SM, Raine L, Fanger H: The use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981
26. Margulies IMK, Höyhtyä M, Evans C, Stracke ML, Liotta LA, Stetler-Stevenson WG: Urinary type IV collagenase elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidem Biomar Prev 467-474, 1992
27. Autio-Harmainen H, Hurskainen T, Niskasaari K, Höyhtyä M, Tryggvason K: Simultaneous expression of 72 kilodalton type IV collagenase and type IV collagen al(IV) chain genes by cells of early human placenta and gestational endometrium. Lab Invest 67: 191-200, 1992
28. Autio-Harmainen H, Karttunen T, Hurskainen T, Höyhtyä M, Kauppila A, Tryggvason K: Expression of 72 kDa type IV collagenase in benign and malignant ovarian tumors. Lab Invest 69: 312-321, 1993
29. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481, 1958
30. Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103: 1237-1241, 1999
31. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix-metalloproteinase-2 immunocreactive protein, a marker of aggressiveness in breast carcinoma. Cancer 83: 1153-1162, 1998
32. Väisänen A, Tuominen H, Kallioinen M, TurpeenniemiHujanen T' Matrix metalloproteinase-2 (72 kDa type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have a prognostic value. J Pathol 180: 283-289, 1996
33. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T: Prognostic value of MMP-2 immunocreactive protein (72 kDa type IV collagenase) in primary skin melanoma. J Pathol 186: 51-58, 1998
34. Väisänen A, Kallioinen M, von Dickhoff K, Laatikainen L, Höyhtyä M, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) immunocreactive protein. A new prognostic marker in uveal melanoma? J Patrol 188: 56-62, 1999
35. Barozzi C, Ravarioli M, D'Errico A, Grazi GL, Poggioli G, Cavrini G, Mazziotti A, Grigioni WF: Relevance of biologic markers in colorectal carcinoma. Cancer 94: 647-657, 2002